新型抗-CD38迈泽妥单抗对输血前检测试验的干扰及处理措施

魏华 ,  任冬霞 ,  赵静雅 ,  穆士杰 ,  杨龙飞

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 784 -788.

PDF (2463KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 784 -788. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.06.012
论著

新型抗-CD38迈泽妥单抗对输血前检测试验的干扰及处理措施

作者信息 +

Interference and treatment strategy of a novel anti-CD38 antibody-mezagitamab in pre-transfusion test

Author information +
文章历史 +
PDF (2521K)

摘要

目的 研究新型抗-CD38 迈泽妥单抗对输血前检测试验的具体干扰情况,并构建一种有效的免疫磁珠处理方法以消除该干扰,同时评估其对其他血型系统的影响及处理的时效性,为临床安全输血提供实验依据和解决方案。方法 合成装载 MOLP8 细胞蛋白的免疫磁珠。 检测不同浓度迈泽妥单抗模拟标本的抗筛结果,并验证该免疫磁珠对迈泽妥单抗干扰的消除效果;评估免疫磁珠吸附迈泽妥单抗后对其他血型系统抗原抗体反应的影响;并对免疫磁珠消除干扰的时效性进行研究。结果 成功合成装载 MOLP8 细胞蛋白的免疫磁珠;免疫磁珠能有效消除不同浓度迈泽妥单抗对输血前检测的干扰,且该消除干扰同时对其他血型系统检出无影响,时效性可稳定维持 2 周。结论 合成的免疫磁珠可有效、特异地消除迈泽妥单抗对输血前血清学检测的干扰,且不影响其他血型系统的检测,有望为接受迈泽妥单抗治疗患者的安全输血提供一定的理论依据。

Abstract

Objective To investigate the specific interference of the novel anti-CD38 antibody mezagitamab in pre-transfusion testing, establish an immunomagnetic bead pre-treatment method to eliminate it, and evaluate its impact on other blood group systems and clinical timeliness, thereby providing experimental evidence and a solution for safe transfusion. Methods MOLP8 cellular protein coated immunomagnetic beads were prepared. Unexpected antibody screening was performed on simulated samples with different mezagitamab concentrations to verify the interference elimination effect. The impact of immunomagnetic bead adsorption of mezagitamab on antigenantibody reactions in other blood group systems was assessed, and the duration of the interferenceeliminating effect was studied. Results MOLP8-coated immunomagnetic beads were successfully prepared, which effectively eliminated mezagitamab interference at different concentrations without affecting other blood group detection, with a stable effect for 2 weeks. Conclusion MOLP8 cellular protein-coated immunomagnetic beads efficiently and specifically eliminate mezagitamab-induced pre-transfusion testing interference without affecting other blood groups, providing a theoretical basis for safe transfusion in patients receiving mezagitamab therapy.

关键词

迈泽妥单抗 / CD38 / 输血前 / 干扰 / 消除策略

Key words

mezagitamab / CD38 / pre-transfusion testing / interference / elimination strategy

引用本文

引用格式 ▾
魏华,任冬霞,赵静雅,穆士杰,杨龙飞. 新型抗-CD38迈泽妥单抗对输血前检测试验的干扰及处理措施[J]. 中国输血杂志, 2026, 39(6): 784-788 DOI:10.13303/j.cjbt.issn.1004-549x.2026.06.012

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

FRERICHS K A,NAGY N A,LINDENBERGH P L,et al. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience[J].Expert Rev Clin Immunol,2018,14(3):197-206.

[2]

KUTER D,CHEN Y F,COOPER N,et al. Trial in progress:Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia[J].Blood, 2025, 146(1):3049.

[3]

KRISHNAN A Y,PATEL K K,MOHAN M,et al. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/ refractory multiple myeloma[J].Blood Neoplasia, 2024, 1(4):100043.

[4]

CHEN H,QIU Y,YIN Z,et al. Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis:a Bayesian network analysis[J].Front Immunol, 2023, 14:1280226.

[5]

YE X,ZHANG J,SONG M,et al. Evolving understandings for the roles of CD38 protein in autoimmunity and autoimmune disease[J].Clin Exp Immunol, 2026,220(1):UXAG014.

[6]

魏华,赵静雅,富文达,等. MOLP8 细胞系用于消除达雷妥尤单抗对输血前相容性检测造成的干扰[J].临床输血与检验,2025, 27(5):643-648.

[7]

WEI H, ZHAO J Y, FU W D, et al. MOLP8 cell line eliminating the interference of daratumumab on the compatibility test in pretransfusion[J].J Clin Transfus Lab Med,2025,27(5):643-648.

[8]

糜坚青,蔡晓红,王少元,等. CD38 单克隆抗体对输血相容性检测干扰及其应对方案的专家共识[J].中国输血杂志,2021, 34(4):327-334.

[9]

MI J Q, CAI X H, WANG S Y, et al. Interference of CD38 monoclonal antibody in blood compatibility testing and its countermeasures:A general consensus among experts[J].Chin J Blood Transfusion,2021,34 (4):327-334.

[10]

张警丹,孙佳丽,杜瑞辉,等. 去除雷达木干扰输血相容性检测的方法及输血疗效评估对比[J].中国输血杂志,2024, 37(2):151-157.

[11]

ZHANG J D, SUN J L, DU R H, et al. Removing the interference of daratumumab on transfusion compatibility testing and comparison of transfusion efficacy[J].Chin J Blood Transfusion, 2024,37 (2):151-157.

[12]

胡艳,卞茂红,鲍静. 达雷妥尤单抗对输血相容性试验的影响及改良 DTT 法消除干扰的研究[J].临床输血与检验,2026, (1):70-74.

[13]

HU Y, BIAN M H, BAO J. The effect of daratumumab on blood transfusion compatibility testing and the study on elimination of interference using a modified DTT method[J].J Clin Transfus Lab Med,2026,(1):70-74.

[14]

TENORIO M,MORENO JIMÉNEZ G,GARCÍA GUTIÉRREZ V,et al. Validation of daraex to resolve daratumumab-induced interferences in pre-transfusion screen tests[J].Blood, 2019, 134(1):4983.

[15]

SAMPATH V S. Isatuximab-based therapy for multiple myeloma[J].N Engl J Med,2025,392(5):518-519.

[16]

MURPHY M F,RAJBHANDARY S,CARAYIANNIS S,et al. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing[J].Transfusion, 2024, 64(7):1217-1222.

[17]

SINGH N,STAVES J,STORRY J R,et al. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy[J].Transfusion, 2023, 63(12):2377-2383.

基金资助

西安市科技计划项目(25YXYJYB00145)

唐都医院学科助推计划(2024JSYX018)

AI Summary AI Mindmap
PDF (2463KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉